Bortezomib plus melphalan and prednisone (VMP regimen) as the initial treatment for IgE multiple myeloma: a case study

被引：8

作者：

Sato, Hiroyuki ^{[1
]}

Komiya, Yusuke ^{[1
]}

Hoshino, Shigeru ^{[1
]}

机构：

[1] Saitama Red Cross Hosp, Dept Hematol, Chuo Ku, Saitama 3388553, Japan

来源：

INTERNATIONAL JOURNAL OF HEMATOLOGY | 2014年 / 99卷 / 06期

关键词：

Multiple myeloma; IgE; Bortezomib; VMP regimen; Initial treatment; PLASMA-CELL LEUKEMIA; MAINTENANCE; THALIDOMIDE; EFFICACY; TRIAL; LEVEL; RARE;

D O I：

10.1007/s12185-014-1571-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Patients with IgE multiple myeloma have poor prognosis. Due to the rarity of this condition, no standard treatment has been developed. As the VMP regimen (bortezomib plus melphalan and prednisone) has been reported to be highly effective in the treatment of other types of myeloma, we treated a patient with newly diagnosed IgE myeloma using the VMP regimen. Her myeloma responded well to VMP regimen. The results of this case report thus suggest that physicians may consider VMP regimen for use as the initial treatment for IgE myeloma.

引用

页码：786 / 789

页数：4

共 50 条

[1] Bortezomib plus melphalan and prednisone (VMP regimen) as the initial treatment for IgE multiple myeloma: a case study
Hiroyuki Sato
Yusuke Komiya
Shigeru Hoshino
International Journal of Hematology, 2014, 99 : 786 - 789
[2] Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
San Miguel, Jesus F.
Schlag, Rudolf
Khuageva, Nuriet K.
Dimopoulos, Meletios A.
Shpilberg, Ofer
Kropff, Martin
Spicka, Ivan
Petrucci, Maria T.
Palumbo, Antonio
Samoilova, Olga S.
Dmoszynska, Anna
Abdulkadyrov, Kudrat M.
Schots, Rik
Jiang, Bin
Mateos, Maria-Victoria
Anderson, Kenneth C.
Esseltine, Dixie L.
Liu, Kevin
Cakana, Andrew
van de Velde, Helgi
Richardson, Paul G.
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (09): : 906 - 917
[3] Bortezomib plus Melphalan and Prednisone for Multiple Myeloma
Avvisati, Giuseppe
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (24): : 2613 - 2613
[4] Bortezomib-Melphalan-Prednisone (VMP) Versus MP as Initial Treatment for Very Elderly Patients With Newly Diagnosed Multiple Myeloma
Kim, Min Kyoung
Kim, Kihyun
Yoon, Do Hyun
Suh, Cheolwon
Moon, Joon Ho
Lee, Yoo Jin
Lee, Jae Hoon
Jung, Sung-Hoon
Lee, Je-Jung
Kim, Hyo Jung
Bae, Sung Hwa
Kim, Jin Seok
Lee, Jeong-Ok
Eom, Hyeon Seok
Lee, Won-Sik
Kang, Hye Jin
Mun, Yeung-Chul
Do, Young Rok
Hyun, Myung Soo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E70 - E70
[5] DARATUMUMAB PLUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (D-VMP) VERSUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (VMP) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS) INELIGIBLE FOR TRANSPLANT: A PHASE 3 RANDOMIZED STUDY (ALCYONE)
Mateos, M., V
Dimopoulos, M. A.
Cavo, M.
Suzuki, K.
Jakubowiak, A.
Knop, S.
Doyen, C.
Lucio, P.
Nagy, Z.
Kaplan, P.
Pou
Cook, M.
Grosicki, S.
Crepaldi, A.
Liberati, A. M.
Campbell, P.
Shelekhova, T.
Yoon, S. S.
Iosava, G.
Fujisaki, T.
Garg, M.
Chiu, C.
Wang, J.
Carson, R.
Crist, W.
Deraedt, W.
Nguyen, H.
Qi, M.
San-Miguel, J.
HAEMATOLOGICA, 2018, 103 : 22 - 22
[6] Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)
Mateos, Maria-Victoria
Dimopoulos, Meletios A.
Cavo, Michele
Suzuki, Kenshi
Jakubowiak, Andrzej J.
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Kaplan, Polina
Pour, Ludek
Cook, Mark
Grosicki, Sebastian
Crepaldi, Andre H.
Liberati, Anna Marina
Campbell, Philip
Shelekhova, Tatiana
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Chiu, Christopher
Wang, Jianping
Carson, Robin
Crist, Wendy
Deraedt, William
Nguyen, Marie
Qi, Ming
San-Miguel, Jesus F.
BLOOD, 2017, 130
[7] Efficacy and safety of Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) versus Bortezomib, Melphalan, and Prednisone (VMP) in Chinese patients with newly diagnosed Multiple Myeloma: OCTANS
Fu, Weijun
Huang, Honghui
Li, Wei
An, Gang
Cai, Zhen
Jin, Jie
Wang, Yafei
Chim, Chor Sang
Qi, Ming
Wang, Jianping
Song, Yang
Jia, Bin
Yang, Xue
Liu, Wenyu
Li, Yunan
Zhang, Renyi
Hou, Jian
Wang, Jianxiang
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S125 - S125
[8] Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study
Morabito, Fortunato
Bringhen, Sara
Larocca, Alessandra
Wijermans, Pierre
Victoria Mateos, Maria
Gimsing, Peter
Mazzone, Carla
Gottardi, Daniela
Omede, Paola
Zweegman, Sonja
Jose Lahuerta, Juan
Zambello, Renato
Musto, Pellegrino
Magarotto, Valeria
Schaafsma, Martijn
Oriol, Albert
Juliusson, Gunnar
Cerrato, Chiara
Catalano, Lucio
Gentile, Massimo
Isabel Turel, Ana
Liberati, Anna Marina
Cavalli, Maide
Rossi, Davide
Passera, Roberto
Rosso, Stefano
Beksac, Meral
Cavo, Michele
Waage, Anders
San Miguel, Jesus
Boccadoro, Mario
Sonneveld, Pieter
Palumbo, Antonio
Offidani, Massimo
AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (04) : 355 - 362
[9] The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment
Garrison, Louis P., Jr.
Wang, Si-Tien
Huang, Hui
Ba-Mancini, Abbie
Shi, Hongliang
Chen, Kristina
Korves, Caroline
Dhawan, Ravinder
Cakana, Andrew
van de Velde, Helgi
Corzo, Deyanira
Duh, Mei Sheng
ONCOLOGIST, 2013, 18 (01): : 27 - 36
[10] Copy Number Variations Could Predict the Outcome of Bortezomib Plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
Kim, Myungshin
Lee, Shin Hyo
Kim, Jiyeon
Lee, Sung-Eun
Kim, Yoo-Jin
Min, Chang-Ki
GENES CHROMOSOMES & CANCER, 2015, 54 (01): : 20 - 27

← 1 2 3 4 5 →